BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024…
Tag: PR Newswire
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations…
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations…
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily…
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily…
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,…
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,…
NEW YORK, Dec. 8, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Toronto-Dominion Bank (NYSE: TD) between February 29, 2024 and October 9, 2024, both dates inclusive (the “Class Period”), of the important December 23,…
NEW YORK, Dec. 8, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Toronto-Dominion Bank (NYSE: TD) between February 29, 2024 and October 9, 2024, both dates inclusive (the “Class Period”), of the important December 23,…
NEW YORK, Dec. 8, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Symbotic Inc. (NASDAQ: SYM) between February 8, 2024 and November 26, 2024, both dates inclusive (the “Class…
